Neuroone Medical Technologies (NMTC) Equity Ratio (2016 - 2026)
Neuroone Medical Technologies filings provide 15 years of Equity Ratio readings, the most recent being 0.68 for Q1 2026.
- On a quarterly basis, Equity Ratio rose 170.46% to 0.68 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.68, a 170.46% increase, with the full-year FY2025 number at 0.66, up 328.37% from a year prior.
- Equity Ratio hit 0.68 in Q1 2026 for Neuroone Medical Technologies, down from 0.75 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.93 in Q1 2022 to a low of 0.15 in Q3 2024.
- Median Equity Ratio over the past 5 years was 0.75 (2025), compared with a mean of 0.67.
- Biggest five-year swings in Equity Ratio: tumbled 80.17% in 2024 and later skyrocketed 328.37% in 2025.
- Neuroone Medical Technologies' Equity Ratio stood at 0.85 in 2022, then fell by 10.3% to 0.76 in 2023, then tumbled by 40.44% to 0.45 in 2024, then soared by 65.13% to 0.75 in 2025, then fell by 8.46% to 0.68 in 2026.
- The last three reported values for Equity Ratio were 0.68 (Q1 2026), 0.75 (Q4 2025), and 0.66 (Q3 2025) per Business Quant data.